Literature DB >> 33875720

Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation.

Martin W Hümmert1,2, Michael Stadler3, Florian Wegner4,5, Thomas Skripuletz4,5, Lothar Hambach3, Stefan Gingele4,5, Martin Bredt6, Mike P Wattjes7, Gudrun Göhring8, Letizia Venturini3, Nora Möhn4,5, Martin Stangel4,5, Corinna Trebst4,5, Arnold Ganser3.   

Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a curative treatment for hematologic malignancies. Acute and chronic graft-versus-host disease (GvHD) are the major immune-mediated complications after alloHSCT. However, there is controversy whether neurologic complications after alloHSCT might represent manifestations of GvHD. We report three patients who acquired distinct, severe immune-mediated peripheral or central nervous system diseases after alloHSCT without other, concomitant GvHD manifestations. One patient had been diagnosed with B-cell chronic lymphocytic leukemia and two patients with high risk myelodysplastic syndrome. Patient #1 presented as LGI1- and GAD-IgG positive immune-mediated encephalitis, patient #2 was diagnosed with MOG-IgG positive encephalomyelitis, and patient #3 had chronic inflammatory polyneuropathy associated with SSA(Ro)-IgG positive Sjögren's syndrome. 100% donor chimerism was detectable in the peripheral blood in all three. The specific antibodies were undetectable in donors' and patients' blood before alloHSCT suggesting that the antibodies had arisen from the transplanted donor immune system. Early intensive immunotherapy led to improvement of clinical symptoms and stability of the neurological disease, however, at the cost of losing the graft-versus-malignancy effect in one patient. In conclusion, we provide evidence of isolated, severe allo-immune diseases of the peripheral and central nervous system as complications of alloHSCT ("neuro-GvHD"). Interdisciplinary surveillance and thorough diagnostic work-up are needed for early diagnosis and treatment of neuro-immunologic complications after alloHSCT to improve the otherwise poor outcome.

Entities:  

Year:  2021        PMID: 33875720     DOI: 10.1038/s41598-021-87989-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  2 in total

1.  Standards for quantification of EMG and neurography. The International Federation of Clinical Neurophysiology.

Authors:  E Stålberg; B Falck; A Gilai; J Jabre; M Sonoo; K Todnem
Journal:  Electroencephalogr Clin Neurophysiol Suppl       Date:  1999

2.  Immune-mediated myelopathy after allogeneic marrow transplantation.

Authors:  H Openshaw; N E Slatkin; P M Parker; S J Forman
Journal:  Bone Marrow Transplant       Date:  1995-04       Impact factor: 5.483

  2 in total
  3 in total

Review 1.  Hematopoietic Stem Cell Transplantation for Neurological Disorders: A Focus on Inborn Errors of Metabolism.

Authors:  Pedro de Vasconcelos; João F Lacerda
Journal:  Front Cell Neurosci       Date:  2022-05-26       Impact factor: 6.147

Review 2.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

Review 3.  Acute Graft-Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System.

Authors:  Janaki Manoja Vinnakota; Robert Zeiser
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.